Payer Perspectives in Vitiligo: Optimizing Patient Outcomes With Novel Therapeutic Approaches

A panel of experts discuss the diagnosis and pathophysiology of vitiligo.

Chesahna Kindred, M.D., MBA, FAAD, and Renata Block, PA-C, review areas of the body that are typically affected, and are more problematic to manage, in patients with vitiligo. Comorbidities that put certain patients at higher risk than others are also discussed.

Gary M. Owens, M.D., discusses the economic costs associated with vitiligo and the impact this disease has had on the U.S. health care system in general.

Renata Block, PA-C, analyzes a study on how vitiligo affects different socioeconomic groups disproportionately.

Chesahna Kindred, M.D., MBA, FAAD, reviews mental health issues that patients with vitiligo are at increased risk for.

Experts explain their approach to the treatment of a new patient with vitiligo and the role of phototherapy in their practice.

Experts review the benefits and side effects of off-label treatments for patients with vitiligo such as corticosteroids, tacrolimus, pimecrolimus or calcipotriene (in combination with corticosteroids).

Chesahna Kindred, M.D., MBA, FAAD, and Renata Block, PA-C, describe how ruxolitinib works differently from other topicals traditionally used in the treatment of vitiligo.

Experts review which patients with vitiligo they would consider using ruxolitinib in.

Gary M. Owens, M.D., explains how ruxolitinib fits into the treatment pathway for patients with vitiligo from a payer perspective.

Experts review the main side effects of ruxolitinib, how to monitor for them in your practice, and the key takeaways for clinicians and payers to know about the two phase 3 trials that led to the approval of ruxolitinib in vitiligo.

Gary M. Owens, M.D., and Chesahna Kindred, M.D., MBA, FAAD, discuss how an optimal multidisciplinary care model for patients with vitiligo can be achieved among providers, pharmacists and payers.

Renata Block, PA-C, and Chesahna Kindred, M.D., MBA, FAAD, explain how organizations addresses barriers to medication access (co-pay cards, patient coordinators) for novel vitiligo therapies.

Gary M. Owens, M.D., explains how an organization weighs the potential clinical outcomes for patients versus the cost of novel therapies for vitiligo.

Chesahna Kindred, M.D., MBA, FAAD, examines how treatment can affect the quality of life in patients with vitiligo.

Renata Block, PA-C, and Gary M. Owens, M.D., explore the access considerations for patients with vitiligo in special populations and review resources that clinicians and payers can share with patients with vitiligo.

Chesahna Kindred, M.D., MBA, FAAD, reviews the vitiligo support groups recommended for patients.